Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Z Benton

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Urology|June 4, 2021
First Case of a Term Male Born with Aphallia and Complete Urethral AtresiaRachel P Vaizer, John Z Benton, Bradley A Morganstern
Urology|July 17, 2022
EDITORIAL COMMENTJohn Z Benton, Christopher J D Wallis, Zachary Klaassen
Current Medical Research and Opinion|December 8, 2020
Cost-effectiveness of first-line treatments in metastatic renal cell carcinomaJohn Z Benton, Zachary Klaassen, Christopher J D Wallis
Urology|October 5, 2019
EDITORIAL COMMENTJohn Z Benton, Atul Lodh, Christopher J D Wallis, et al.
Cancer|September 22, 2021
Mental health screening and diagnosis in cancer patients: Impact on mortality and suggestion of racial biasJohn Z Benton, Cristiane D Bergerot, Phillip Woodruff, et al.
Urology|February 9, 2020
EDITORIAL COMMENTSoum D Lokeshwar, John Z Benton, Sherita A King, et al.
Preventive Medicine|April 5, 2020
The association between physician trust and smoking cessation: Implications for motivational interviewingJohn Z Benton, Atul Lodh, Archibald M Watson, et al.
World Journal of Urology|December 6, 2022
Prostate cancer mortality rates in low- and favorable intermediate-risk active surveillance patients: a population-based competing risks analysisRashid K Sayyid, John Z Benton, William C Reed, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 31, 2021
Active surveillance in favorable intermediate-risk prostate cancer patients: Predictors of deferred intervention and treatment choiceRashid K Sayyid, Laurence Klotz, John Z Benton, et al.
Urologic Oncology|March 26, 2021
Pathologic upgrading in favorable intermediate risk active surveillance patients: Clinical heterogeneity and implications for active surveillance decisionRashid K Sayyid, William C Reed, John Z Benton, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Urology|June 4, 2021
First Case of a Term Male Born with Aphallia and Complete Urethral AtresiaRachel P Vaizer, John Z Benton, Bradley A Morganstern
Urology|July 17, 2022
EDITORIAL COMMENTJohn Z Benton, Christopher J D Wallis, Zachary Klaassen
Current Medical Research and Opinion|December 8, 2020
Cost-effectiveness of first-line treatments in metastatic renal cell carcinomaJohn Z Benton, Zachary Klaassen, Christopher J D Wallis
Urology|October 5, 2019
EDITORIAL COMMENTJohn Z Benton, Atul Lodh, Christopher J D Wallis, et al.
Cancer|September 22, 2021
Mental health screening and diagnosis in cancer patients: Impact on mortality and suggestion of racial biasJohn Z Benton, Cristiane D Bergerot, Phillip Woodruff, et al.
Urology|February 9, 2020
EDITORIAL COMMENTSoum D Lokeshwar, John Z Benton, Sherita A King, et al.
Preventive Medicine|April 5, 2020
The association between physician trust and smoking cessation: Implications for motivational interviewingJohn Z Benton, Atul Lodh, Archibald M Watson, et al.
World Journal of Urology|December 6, 2022
Prostate cancer mortality rates in low- and favorable intermediate-risk active surveillance patients: a population-based competing risks analysisRashid K Sayyid, John Z Benton, William C Reed, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 31, 2021
Active surveillance in favorable intermediate-risk prostate cancer patients: Predictors of deferred intervention and treatment choiceRashid K Sayyid, Laurence Klotz, John Z Benton, et al.
Urologic Oncology|March 26, 2021
Pathologic upgrading in favorable intermediate risk active surveillance patients: Clinical heterogeneity and implications for active surveillance decisionRashid K Sayyid, William C Reed, John Z Benton, et al.
Pageof 2